5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.
A six month controlled study of 5-fluorouracil in the treatment of scleroderma showed a modest benefit in skin scores, Raynaud's phenomenon, and patients' global assessment. Visceral organ and hand function were unaffected. Mild to moderate toxicity was common in the 5-fluorouracil treated patients but usually responded to dose reduction. Two patients receiving 5-fluorouracil died from causes seemingly unrelated to treatment. Significant clinical improvement in scleroderma was not noted in the first six months of treatment with 5-fluorouracil.
Casas
J A
JA
Department of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.
Saway
P A
PA
Villarreal
I
I
Nolte
C
C
Menajovsky
B L
BL
Escudero
E E
EE
Blackburn
W D
WD
Alarcón
G S
GS
Subauste
C P
CP
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
D005472:Fluorouracil